Biocept Akcija

Biocept Goodwill

Delisted

Biocept (BIOC) Firmos sąžinė 2026-08-11 dieną.

Goodwill

0,00USD

Paskutinį kartą atnaujinta:

Biocept Firmos sąžinė yra 2026 0,00 USD. Biocept Firmos sąžinė buvo 2025 0,00 USD. Tai sumažėjo % mažesnis lyginant su praėjusiais metais.
Access this data via the Eulerpool API

Biocept Akcijų analizė

Ką veikia Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept yra viena populiariausių kompanijų Eulerpool.com.

Dažniausiai užduodami klausimai apie Biocept akciją

Eulerpool rasite visą Firmos sąžinė Biocept istorinę raidą nuo 2006 m. – su metinėmis reikšmėmis, grafikais ir išsamiomis analizėmis.

Firmos sąžinė yra priemokanis, mokamas virš tikrojo rinkos vertės atliekant įsigijimą. Jis atspindi nematerialią vertę, tokią kaip ženklo pripažinimas, klientų santykiai ir intelektinė nuosavybė.

Firmos sąžinė USD yra svarbus investuotojams veiksnys. Šios rodiklio pokyčiai gali signalizuoti apie pagerintas ar pablogėjusias finansines sąlygas, tiesiogiai paveikdami akcijos kainą. Eulerpool platformoje galite sekti Firmos sąžinė Biocept istorinę raidą ir realią laiko informaciją.

Access this data via the Eulerpool API

Balanso lapas — Biocept

Visi pagrindiniai rodikliai — Biocept